DUSP2

Overview

DUSP2 functions as a negative regulator of MAPK signaling, particularly affecting the ERK1/2 pathway. DUSP2 mutations have been reported in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL), T-cell/histiocyte-rich large B-cell lymphoma (T/HRLBCL)schuhmacherJUNBDUSP2SGK12019b?,hartmannHighlyRecurrentMutations2016b? and they are relatively frequent in DLBCL.
DUSP2 is one of a number of genes affected by aberrant somatic hypermutation in B-cell lymphomas, which complicates the interpretation of mutations at this locus. These mutations are associated with the ST2 genetic subgroup of DLBCL. This gene has some recurrent sites of mutations (hot spots). The mutation pattern in DLBCL implies the preferential accumulation of inactivating mutations.

History

%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%% timeline title Publication timing 2012-03-06 : Lohr : DLBCL 2013-08-15 : Morin : DLBCL 2017-10-10 : Reddy : DLBCL 2018-04-12 : Schmitz : DLBCL

Relevance tier by entity

Entity Tier Description
PMBL 1 high-confidence PMBL/cHL/GZL genedunsCharacterizationDLBCLPMBL2021b?
DLBCL 1-a aSHM target and high-confidence DLBCL gene [1]lohrDiscoveryPrioritizationSomatic2012a?
FL 2-a aSHM target; Although recurrent, the relevance of mutations in FL is tenuous

Mutation incidence in large patient cohorts (GAMBL reanalysis)

Entity source frequency (%)
DLBCL GAMBL genomes 10.13
DLBCL Schmitz cohort 12.55
DLBCL Reddy cohort 9.71
DLBCL Chapuy cohort 4.27
FL GAMBL genomes 2.31

Mutation pattern and selective pressure estimates

Entity aSHM Significant selection dN/dS (missense) dN/dS (nonsense)
BL Yes No 1.258 17.913
DLBCL Yes No 1.537 12.012
FL Yes No 3.206 0.000

aSHM regions

chr_name hg19_start hg19_end region regulatory_comment
chr2 96808901 96811913 intron-1 enhancer

DUSP2 Hotspots

Chromosome Coordinate (hg19) ref>alt HGVSp
chr2 96810877 C>G D73H
chr2 96810865 G>A R77W
chr2 96810842 C>G E84D
chr2 96810841 G>C L85V
chr2 96810730 G>A P122S
chr2 96810717 T>C Y126C
chr2 96810706 C>T G130R
chr2 96810597 C>T C138Y
chr2 96810582 C>T C143Y
chr2 96810574 C>T A146T

View coding variants in ProteinPaint hg19 or hg38

View all variants in GenomePaint hg19 or hg38

DUSP2 Expression

References

1.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.